Stay updated on Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.

Latest updates to the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page revision was updated from v3.6.2 to v3.6.3, signaling a page refresh. This appears to be a metadata-level update rather than a change to the study details.SummaryDifference0.1%

- Check23 days agoChange DetectedThe page now displays an updated revision label from v3.6.0 to v3.6.2, indicating a newer build of the page without changes to visible content or features.SummaryDifference0.1%

- Check37 days agoChange DetectedThe page now shows recruitment status as 'No longer looking for participants', indicating enrollment for this study has ended. New help and navigation sections—How to Read a Study Record, Common Questions, and How to Join a Study—were added, and the Interventions/Treatment header was updated; a revision note (Revision: v3.6.0) is also included.SummaryDifference0.4%

- Check44 days agoChange DetectedThe page footer now includes Moffitt branding and related trial links. The revision label changed from v3.5.4 to v3.5.5.SummaryDifference0.3%

- Check51 days agoChange DetectedThe page’s footer now omits the H. Lee Moffitt Cancer Center branding and the sponsor-provided links to drug information, study documents, and helpful resources. This changes how the page references its affiliated institution and directs users to related materials.SummaryDifference0.3%

- Check66 days agoChange DetectedRevision label updated from v3.5.3 to v3.5.4, indicating a minor site/template update.SummaryDifference0.1%

Stay in the know with updates to Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab + Lymphodepletion + ACT + HD IL-2 Melanoma Mets Clinical Trial page.